Immunic, Inc.
IMUX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $170,940 | $92,192 | $110,465 | $90,151 |
| - Cash | $35,132 | $55,310 | $14,304 | $35,668 |
| + Debt | $126 | $979 | $975 | $1,004 |
| Enterprise Value | $135,934 | $37,861 | $97,136 | $55,487 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$35 |
| % Margin | – | – | – | – |
| EBITDA | -$25,579 | -$27,040 | -$26,782 | -$25,140 |
| % Margin | – | – | – | – |
| Net Income | -$25,579 | -$26,820 | -$25,473 | -$25,175 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.2 | -0.25 | -0.28 |
| % Growth | 35% | 20% | 10.7% | – |
| Operating Cash Flow | -$20,140 | -$24,609 | -$21,776 | -$22,963 |
| Capital Expenditures | -$67 | -$36 | -$47 | -$3 |
| Free Cash Flow | -$20,207 | -$24,645 | -$21,823 | -$22,966 |